Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Fritah H., Graciotti M., Lai-Lai Chiang C., Huguenin-Bergenat A.L., Petremand R., Ahmed R., Guillaume P., Schmidt J., Stevenson B.J., Gfeller D. et al., 2023/04/21. iScience, 26 (4) p. 106288. Peer-reviewed.